IMPUF vs. CDTX

Last updated Jun 4, 2026

IMPUF (Impala Platinum Holdings Ltd) and CDTX (Cidara Therapeutics, Inc.) are both stocks. IMPUF operates in Other Precious Metals & Mining (Basic Materials), while CDTX operates in Biotechnology (Healthcare). At a 0.02 correlation, their price movements are largely independent.

Performance

IMPUF vs. CDTX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Impala Platinum Holdings Ltd (IMPUF) and Cidara Therapeutics, Inc. (CDTX). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

IMPUF

• 1D: -1.10%
• 1M: -2.86%
• YTD: -11.27%
• 6M: 20.64%
• 1Y: 91.01%
• 3Y*: 18.89%
• 5Y*: -1.71%
• 10Y*: —

CDTX

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

IMPUF vs. CDTX - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
IMPUF Impala Platinum Holdings Ltd	-11.27%	200.45%	12.15%	-60.02%	-5.41%	12.03%	50.30%	410.99%
CDTX Cidara Therapeutics, Inc.	0.22%	721.76%	69.27%	4.98%	-40.45%	-36.50%	-47.92%	42.22%

Correlation

The correlation between IMPUF and CDTX is 0.04, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.04
Correlation (3Y) Calculated over the trailing 3-year period	0.02
Correlation (5Y) Calculated over the trailing 5-year period	0.03
Correlation (All Time) Calculated using the full available price history since Feb 26, 2019	0.02

Fundamentals

Market Cap IMPUF : $12.15B CDTX : $3.44B
EPS IMPUF : -$9.66 CDTX : -$11.88
PB Ratio IMPUF : 0.13 CDTX : 8.15
Total Revenue (TTM) IMPUF : $188.26B CDTX : $0.00
Gross Profit (TTM) IMPUF : $17.78B CDTX : -$45.00M
EBITDA (TTM) IMPUF : $29.69B CDTX : -$189.91M

Return for Risk

IMPUF vs. CDTX — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IMPUF

IMPUF Risk / Return Rank: 77
IMPUF Sharpe Ratio Rank: 76
IMPUF Sortino Ratio Rank: 74
IMPUF Omega Ratio Rank: 84
IMPUF Calmar Ratio Rank: 76
IMPUF Martin Ratio Rank: 74

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

IMPUF vs. CDTX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Impala Platinum Holdings Ltd (IMPUF) and Cidara Therapeutics, Inc. (CDTX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	IMPUF	CDTX	Difference
Sharpe ratio Return per unit of total volatility	1.18	—	—
Sortino ratio Return per unit of downside risk	1.95	—	—
Omega ratio Gain probability vs. loss probability	1.35	—	—
Calmar ratio Return relative to maximum drawdown	2.13	—	—
Martin ratio Return relative to average drawdown	4.45	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	IMPUF	CDTX	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.18	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.03	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.43	—	—

Drawdowns

Drawdown Indicators

	IMPUF	CDTX	Difference
Max Drawdown Largest peak-to-trough decline	-80.80%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-42.87%	—	—
Max Drawdown (3Y) Largest decline over 3 years	-59.31%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-79.84%	—	—
Current Drawdown Current decline from peak	-39.20%	—	—
Average Drawdown Average peak-to-trough decline	-41.79%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	20.51%	—	—

Volatility

Volatility by Period

	IMPUF	CDTX	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.55%	—	—
Volatility (6M) Calculated over the trailing 6-month period	61.16%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	77.74%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	64.06%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	107.33%	—	—

Dividends

IMPUF vs. CDTX - Dividend Comparison

IMPUF's dividend yield for the trailing twelve months is around 1.78%, while CDTX has not paid dividends to shareholders.

Position	TTM	2025	2024	2023	2022	2021	2020
CDTX Cidara Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
IMPUF Impala Platinum Holdings Ltd	1.78%	0.00%	0.00%	6.80%	7.85%	10.80%	1.75%

Financials

Frequently Asked Questions

Can I hold both IMPUF and CDTX in my portfolio?

IMPUF and CDTX have a correlation of 0.04, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.